Related Experiment Video
Updated: May 21, 2025
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Galloylated Toll-Like Receptor 7/8 Agonist Nanovaccine for Enhanced Tumor Antigen Delivery in Personalized
Mengyao Ma1, Ximu Li1, Mingyuan Zhong1
1Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.
Abstract:
Cancer vaccines, a critical technology in cancer immunotherapy, have shown great therapeutic potential. However, traditional vaccines based on tumor cell lysates (TCLs) have shown disappointing results in early clinical trials due to low immunogenicity, in vivo instability, and the inability to codeliver with adjuvants. To address these issues, we developed a nanoparticle vaccine, R848-GA@TCLs, by modifying the toll-like receptor 7/8 (TLR7/8) agonist R848 with gallic acid. This nanovaccine leverages the "capturing" ability of the galloyl moiety to coload TCLs and R848, forming stable nanoparticles. R848-GA@TCLs efficiently target lymph nodes, increasing TCL accumulation 10-fold, and enable the synchronized release of antigens and adjuvants within dendritic cells (DCs). Our results show that R848-GA@TCLs increase with respect to the cross-presentation of tumor antigens, promote the production of pro-inflammatory cytokines, and activate DCs, leading to a significant increase in effector T cells, natural killer (NK) cells, and M1 macrophages. This strong immune response resulted in potent antitumor effects, with R848-GA@TCLs demonstrating efficacy in multiple tumor models by significantly inhibiting tumor growth and metastasis. In conclusion, R848-GA@TCLs represent a personalized cancer vaccine capable of codelivering TCLs and adjuvants, eliciting robust antitumor immune responses, and hold great potential for clinical applications.
Insights
A novel nanoparticle cancer vaccine, R848-GA@TCLs, overcomes limitations of traditional vaccines by co-delivering tumor antigens and adjuvants. This enhances immune cell activation and demonstrates potent antitumor effects in preclinical models.
Area of Science:
- Immunology
- Nanotechnology
- Oncology
Background:
- Traditional cancer vaccines using tumor cell lysates (TCLs) face challenges like low immunogenicity and poor adjuvant co-delivery.
- Existing methods struggle with in vivo instability and inefficient targeting of immune cells.
Purpose of the Study:
- To develop a stable nanoparticle vaccine (R848-GA@TCLs) for enhanced cancer immunotherapy.
- To improve the co-delivery of tumor antigens and toll-like receptor 7/8 (TLR7/8) agonists for robust immune activation.
Main Methods:
- Modification of TLR7/8 agonist R848 with gallic acid to create galloyl-modified R848 (R848-GA).
- Formation of stable nanoparticles (R848-GA@TCLs) for co-loading TCLs and R848-GA.
- Evaluation of nanoparticle targeting, antigen presentation, immune cell activation, and antitumor efficacy in preclinical models.
Main Results:
- R848-GA@TCLs efficiently target lymph nodes, increasing TCL accumulation tenfold.
- Nanoparticles facilitate synchronized antigen and adjuvant release within dendritic cells (DCs).
- Significant increases in effector T cells, NK cells, M1 macrophages, and potent inhibition of tumor growth and metastasis were observed.
Conclusions:
- R848-GA@TCLs represent a promising personalized cancer vaccine platform.
- The nanovaccine elicits robust antitumor immune responses by enhancing antigen presentation and immune cell activation.
- This technology holds significant potential for future clinical applications in cancer immunotherapy.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...